natgillin/translations-raw huggingface dataset:
• Hvis ”ml” markeringen på kraven er højere end den ordinerede dosis, tryk stemplet ind til den ordinerede dosis. 
• If the ‘ml' mark on the collar is more than the prescribed dose, push the plunger to the prescribed dose.
4.5); - riociguat anbefales ikke (se pkt. 
(see section 4.5); - riociguat is not recommended (see section 4.5); - vorapaxar is not recommended (see section 4.5); - fusidic acid in osteo-articular infections is not recommended (see section 4.5); - salmeterol is not recommended (see section 4.5); - rivaroxaban is not recommended (see section 4.5).
Kaletra fås også som 100/25 mg filmovertrukne tabletter. 
Kaletra is also supplied as 100 mg/25 mg film-coated tablets.
Samtidig administration af Kaletra, astemizol og terfenadin er kontraindiceret, da riskoen for alvorlige arytmier forårsaget af disse lægemidler kan øges (se pkt. 
Concomitant administration of Kaletra and astemizole and terfenadine is contraindicated as it may increase the risk of serious arrhythmias from these agents (see section 4.3).
Kaletra må ikke indgives en gang dagligt i kombination med nevirapin. 
Kaletra must not be administered once daily in combination with nevirapine.
Etravirin (Lopinavir/ritonavir tablet 400/100 mg to gange dagligt) 
Etravirine (Lopinavir/ritonavir tablet 400/100 mg BID)
• hårtab; 
• hair loss;
Kaletra filmovertrukne tabletter er svagt gule med påtrykt [Abbott-logo] og ”KC”. 
Kaletra film-coated tablets are pale yellow debossed with [Abbott logo] and “KC”.
Administration sammen med quetiapin er kontraindiceret (se pkt. 
The concomitant administration with quetiapine is contraindicated (see section
- Hvis du opdager, at du har glemt en dosis inden for 12 timer fra det tidspunkt, du skulle have taget din dosis, skal du tage den glemte dosis snarest muligt og derefter fortsætte med at tage din normale dosis til sædvanlig tid, som foreskrevet af din læge. 
− If you notice you miss a dose within 12 hours of your normal dosing time, take your missed dose as soon as possible, and then continue with your normal dose at the regular time as prescribed by your doctor.
Samtidig administration af alfuzosin er kontraindiceret (se pkt. 
The concomitant administration with alfuzosin is contraindicated (see section 4.5).
• Brug den orale doseringssprøjte på 5 ml til at afmåle dosen. 
• Use the 5 ml oral syringe provided to measure the dose.
Kaletra bør ikke anvendes samtidig med apalutamid. 
Concomitant use of Kaletra with apalutamide is not recommended.
AUC: ↑ 5-gange 
AUC: ↑ 5-fold
Anvendelse af avanafil med Kaletra er kontraindiceret (se pkt. 
The use of avanafil with Kaletra is contraindicated (see section 4.3).
Ombitasvir/paritaprevir/ri tonavir + dasabuvir 
Ombitasvir/paritaprevir/rito navir + dasabuvir
- Hvis du opdager, at du har glemt en dosis inden for 6 timer fra det tidspunkt, du skulle have taget din dosis, skal du tage den glemte dosis snarest muligt og derefter fortsætte med at tage din normale dosis til sædvanlig tid, som foreskrevet af din læge. 
− If you notice you miss a dose within 6 hours of your normal dosing time, take your missed dose as soon as possible, and then continue with your normal dose at the regular time as prescribed by your doctor.
hiv-RNA < 400 kopier/ml 
HIV RNA < 400 copies/ml
• Brug den orale doseringssprøjte på 2 ml til at afmåle dosen. 
• Use the 2 ml oral syringe provided to measure the dose.
Gennemsnitlig baseline CD4+ Tcelletal var 838 celler/mm3 og gennemsnitlig baseline plasma hiv-1-RNA var 4,7 log10 kopier/ml. 
Mean baseline CD4+ T-cell count was 838 cells/mm3 and mean baseline plasma HIV-1 RNA was 4.7 log10 copies/ml.
Kaletra filmovertrukne tabletter er gule med påtrykt [Abbott-logo] og ”KA”. 
Kaletra film-coated tablets are yellow debossed with [Abbott logo] and “KA”.
På grund af ritonavirs hæmning af P-gp og/eller CYP3A4. 
Due to P-gp and/or CYP3A4 inhibition by ritonavir.
Mediant CD4-celletal ved baseline var 349 celler/mm3 (interval 72 til 807 celler/mm3) og median plasma-hiv-1-RNA ved baseline var 4,0 log10 kopier/ml (interval 2,9 til 5,8 log10 kopier/ml). 
Median baseline CD4 cell count was 349 cells/mm3 (range 72 to 807 cells/mm3) and median baseline plasma HIV-1 RNA was 4.0 log10 copies/ml (range 2.9 to 5.8 log10 copies/ml).
• hvis du er allergisk over for lopinavir, ritonavir eller et af de øvrige indholdsstoffer i Kaletra 
• you are allergic to lopinavir, ritonavir or any of the other ingredients of Kaletra (see section 6); • you have severe liver problems.
Hvis du eller dit barn har taget for meget Kaletra 
If you or your child take more Kaletra than you should
MÆRKNING, DER SKAL ANFØRES PÅ DEN INDRE EMBALLAGE 200 mg/50 mg tabletter - æske med 1 beholder 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING 200 mg/50 mg tablets - Carton of 1 bottle
hiv-RNA < 400 kopier/ml* 
HIV RNA < 400 copies/ml*
Sekalealkaloider Dihydroergotamin, ergonovin, ergotamin, methylergonovin 
Ergot alkaloids Dihydroergotamine, ergonovine, ergotamine, methylergonovine
Fosamprenavir/ ritonavir (700/100 mg to gange dagligt) 
Fosamprenavir/ ritonavir (700/100 mg
MÆRKNING DER SKAL VÆRE PÅ DEN INDRE EMBALLAGE BEHOLDERETIKET 200 mg/50 mg tabletter - beholderetiket 
PARTICULARS TO APPEAR ON THE ON THE IMMEDIATE PACKAGING 200 mg/50 mg tablets - Bottle label
Lopinavir : AUC: ↔ Cmin: ↓ 20% 
AUC: ↔ Cmin: ↓ 20%
- Hvis du opdager, at du har glemt en dosis 12 timer eller længere fra det tidspunkt, du skulle have taget dosis, skal du ikke tage den glemte dosis. 
− If you notice you miss a dose by more than 12 hours after your normal dosing time, do not take the missed dose.
Brug doseringssprøjten på 5 ml til at klargøre en dosis. 
Use the 5 ml oral dosing syringe to prepare a dose.
Filmovertrukne tabletter Gule med præget [Abbott logo] og “KA”. 
Film-coated tablet Yellow debossed with [Abbott logo] and “KA”.
Hver filmovertrukken tablet indeholder 200 mg lopinavir formuleret sammen med 50 mg ritonavir som farmakokinetisk forstærker. 
Each film-coated tablet contains 200 mg of lopinavir co-formulated with 50 mg of ritonavir as a pharmacokinetic enhancer.
- Hvis du opdager, at du har glemt en dosis 6 timer eller længere fra det tidspunkt, du skulle have taget din dosis, skal du ikke tage den glemte dosis. 
− If you notice you miss a dose by more than 6 hours after your normal dosing time, do not take the missed dose.
Hver filmovertrukken tablet indeholder 100 mg lopinavir formuleret sammen med 25 mg ritonavir som farmakokinetisk forstærker. 
Each film-coated tablet contains 100 mg of lopinavir co-formulated with 25 mg of ritonavir as a pharmacokinetic enhancer.
Skil sprøjten og pumpestemplet ad efter hver dosis Kaletra. 
After each dose of Kaletra separate the plunger and the syringe.
Samtidig administration af Kaletra og cisaprid er kontraindiceret, da riskoen for alvorlige arytmier forårsaget af dette lægemiddel kan øges (se pkt. 
Concomitant administration of Kaletra and cisapride is contraindicated as it may increase the risk of serious arrhythmias from this agent (see section 4.3).
Derved øges risikoen for alvorlige arytmier forårsaget af disse lægemidler (se pkt. 
Thereby, increasing the risk of serious arrhythmias from these agents (see section 4.5).
Delamanid (100 mg 2 gange dagligt) 
Delamanid (100 mg BID)
Kaletra 100 mg/25 mg filmovertrukne tabletter 
Kaletra 100 mg/25 mg film-coated tablets
(80 mg lopinavir/20 mg ritonavir pr. ml)** 
Volume of oral solution twice daily taken with food (80 mg lopinavir/20 mg ritonavir per ml)**
Antiretroviral-erfarne patienter 
Patients with prior antiretroviral therapy
b. Bivirkninger i tabelform 
b. Tabulated list of adverse reactions
Lopinavir/ritonavir 400/100 mg 2 gange dagligt 
Lopinavir/ritonavir 400/100 mg BID
Ætiologien anses dog for at være multifaktoriel (omfattende anvendelse af kortikosteroider, alkoholforbrug, svær immunosuppression, højere Body Mass Index (BMI)). 
Although the etiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to combination antiretroviral therapy (CART).
MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE Ydre emballage af multipakning a 120 (3 æsker a 40 filmovertrukne tabletter) - inklusive blue box, Æske, som indeholder 120 200/50 mg filmovertrukne tabletter 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Outer carton of multipacks of 120 (3 cartons of 40 film-coated 200 mg/50 mg film-coated tablets) - including the blue box
Kombination af bedaquilin og Kaletra bør undgås på grund af risikoen for bedaquilinrelaterede bivirkninger. 
Due to the risk of bedaquiline related adverse events, the combination of bedaquiline and Kaletra should be avoided.
Anvendelse af vardenafil med Kaletra er kontraindiceret (se pkt. 
The use of vardenafil with Kaletra is contraindicated (see section 4.3).
På grund af lopinavir/ritonavirs CYP3A-hæmning forventes koncentrationen af lurasidon at stige. 
Due to CYP3A inhibition by lopinavir/ritonavir, concentrations of lurasidone are expected to increase.
Forhøjede plasmakoncentrationer af avanafil (se pkt. 
Increased plasma concentrations of avanafil (see sections 4.4 and 4.5).
Gennemsnitsbaseline CD4+ T-celletal var 216 celler/mm3 (interval: 20 til 775 celler/mm3) og gennemsnitsbaseline plasma-hiv-1-RNA var 5,0 log10 kopier/ml (interval: 1,7 til 7,0 log10 kopier/ml). 
Mean baseline CD4+ T-cell count was 216 cells/mm3 (range: 20 to 775 cells/mm3) and mean baseline plasma HIV-1 RNA was 5.0 log10 copies/ml (range: 1.7 to 7.0 log10 copies/ml).
AUC: ↑ 13-gange På grund af lopinavir/ritonavirs hæmning af CYP3A. 
AUC: ↑ 13-fold Due to CYP3A inhibition by lopinavir/ritonavir.
4.5), er resulterne af dette studie måske ikke direkte ekstrapolerbare, når andre basis-regime bruges med Kaletra. 
Given the pharmacokinetic interaction between Kaletra and tenofovir (see section 4.5), the results of this study might not be strictly extrapolable when other backbone regimens are used with Kaletra.
Hver ml Kaletra oral opløsning indeholder 80 mg lopinavir og 20 mg ritonavir. 
Each ml of Kaletra oral solution contains 80 mg of lopinavir and 20 mg of ritonavir.
Interaktionstabel 
Interaction table
MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE 100/25 mg tabletter- æske med 1 beholder 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING 100 mg/ 25 mg tablets - Carton of 1 bottle
Brug doseringssprøjten på 2 ml til at klargøre en dosis. 
Use the 2 ml oral dosing syringe to prepare a dose.
Udskillelse af lopinavir i mælk er vist i rottestudier. 
Studies in rats revealed that lopinavir is excreted in the milk.
Rifabutin (moderstof og den aktive 25-O-desacetyl metabolit): AUC: ↑5,7-gange Cmax: ↑3,5-gange 
Rifabutin, 150 mg QD Rifabutin (parent drug and active 25-O-desacetyl metabolite):
Midler mod angina pectoris Ranolazin 
Antianginal Ranolazine
Koncentrationerne kan være nedsat. 
Voriconazole: Concentrations may be decreased.
Samtidig administration af Kaletra og pimozid er kontraindiceret, idet risikoen for alvorlige hæmatologiske stige. 
Concomitant administration of Kaletra and quetiapine is contraindicated as it may increase quetiapine-related toxicity.
Det er også rapporteret, at autoimmune sygdomme (såsom Graves sygdom og autoimmun hepatitis) kan forekomme i tilfælde af immunrekonstitution. 
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reconstitution; however, the reported time to onset is more variable and can occur many months after initiation of treatment.
hiv-RNA < 400 kopier/ml (ITT)* hiv-RNA < 50 kopier/ml (ITT)* 
HIV RNA < 400 copies/ml (ITT)*
NC= Fejl Observerede data 
Observed data
Cmax: ↑ 4,7 gange Cmin: ↑ 14,4 gange 
AUC: ↑ 7.2-fold Cmax: ↑ 4.7-fold Cmin: ↑ 14.4-fold
AUC: ↑ 13-gange 
AUC: ↑ 13-fold
• Hvis ”ml" markering på den sorte ”O” ring er mindre end den ordinerede dosis, træk mere opløsning op til du rammer den ordinerede dosis. 
• If the ‘ml' mark on the black ‘O' ring is less than the prescribed dose, draw up more solution to the prescribed dose.
På grund af lopinavir/ritonavirs CYP3A-hæmning forventes koncentrationen af ranolazin at stige. 
Due to CYP3A inhibition by lopinavir/ritonavir, concentrations of ranolazine are expected to increase.
Kaletra tabletter skal synkes hele og ikke tygges, deles eller knuses. 
Kaletra tablets must be swallowed whole and not chewed, broken or crushed.
Hver ml af Kaletra indeholder 80 mg lopinavir og 20 mg ritonavir. 
Each ml of Kaletra contains 80 mg of lopinavir and 20 mg of ritonavir.
Kaletra 200 mg/50 mg filmovertrukne tabletter 
Kaletra 200 mg/50 mg film-coated tablets
P=0,015 (kohorte I); P< 0,001 (kohorte II). 
Overall failure rate combining the treatment differences across age strata, weighted by the precision of the estimate within each age stratum p=0.015 (Cohort I); p< 0.001 (Cohort II)
Dosis til voksne af Kaletra tabletter (400/100 mg to gange dagligt) kan anvendes til børn på 40 kg eller derover eller med en legemsverflade (BSA)* større end 1,4 m2 . 
The adult dose of Kaletra tablets (400/100 mg twice daily) may be used in children 40 kg or greater or with a Body Surface Area (BSA)* greater than 1.4 m2. For children weighing less than 40 kg or with a BSA between 0.5 and 1.4 m2 and able to swallow tablets, refer to the dosing guideline tables below.
Filmovertrukne tabletter Lysegule med præget [Abbott logo] og “KC”. 
Film-coated tablet Pale yellow debossed with [Abbott logo] and “KC”.
Gennemsnitsbaseline for CD4+ celletæling var 254 celler/mm3 (interval: 4 til 952 celler/mm3) og gennemsnitsbaseline for plasma hiv-1-RNA var 4,3 log10 kopier/ml (interval: 1,7 til 6,6 log10 kopier/ml). 
Mean baseline CD4+ T-cell count was 254 cells/mm3 (range: 4 to 952 cells/mm3) and mean baseline plasma HIV-1 RNA was 4.3 log10 copies/ml (range: 1.7 to 6.6 log10 copies/ml).
MÆRKNING, DER SKAL ANFØRES PÅ DEN INDRE EMBALLAGE 100/25 mg tabletter- beholderetiket 
PARTICULARS TO APPEAR ON THE ON THE IMMEDIATE PACKAGING 100 mg/25 mg tablets - bottle label
Udslæt inklusive makulopapuløst udslæt, dermatit/udslæt inklusive eksem og seboreisk dermatit, nattesved, pruritus Ikke almindelig Alopeci, kapillarit, vaskulit Ikke kendt 
Rash including maculopapular rash, dermatitis/rash including eczema and seborrheic dermatitis, night sweats, pruritus
Øgede plasmakoncentrationer af neratinib, som kan øge risikoen for alvorlige og livstruende reaktioner (se pkt. 
Increased plasma concentrations of neratinib which may increase the potential for serious and/or life-threatening reactions (see section
• hjertemedicin, herunder: digoxin; calciumantagonister (f.eks. felodipin, nifedipin, nicardipin); 
− calcium channel antagonists (e.g. felodipine, nifedipine, nicardipine);
Samtidig administration af encorafenib og Kaletra bør undgås. 
Co-administration of encorafenib and Kaletra should be avoided.
b. Bivirkninger i tableform 
B. PACKAGE LEAFLET
(Lopinavir/ritonavir 400/100 mg 2 gange dagligt fler-dosis) 
(Lopinavir/ritonavir 400/100 mg BID, multiple dose)
Se produktresuméet for colchicin. 
Refer to colchicine prescribing information.
Serumkoncentrationen kan øges på grund af ritonavirs hæmning af CYP3A. 
Serum concentrations may be increased due to CYP3A inhibition by ritonavir.
Samtidig administration af Kaletra og simeprevir anbefales ikke 
It is not recommended to co-administer Kaletra and simeprevir.
Serumkoncentrationen af apalutamid kan øges på grund af lopinavir/ritonavirs CYP3Ahæmning. 
Serum concentrations of apalutamide may be increased due to CYP3A inhibition by lopinavir/ritonavir.
Gennemsnitlig baseline CD4+ T-celletal var 259 celler/mm3 (interval: 2 til 949 celler/ mm3) og gennemsnitlig baseline plasma hiv-1-RNA var 4,9 log10 kopier/ml (interval: 2,6 til 6,8 log10 kopier/ml). 
Mean baseline CD4+ T-cell count was 259 cells/mm3 (range: 2 to 949 cells/ mm3) and mean baseline plasma HIV-1 RNA was 4.9 log10 copies/ml (range: 2.6 to 6.8 log10 copies/ml).
På grund lopinavir/ritonavirs hæmning af CYP3A og P-gp. 
Due to CYP3A and P-gp inhibition by lopinavir/ritonavir.
Gennemsnitlig stigning i CD4+ T-celletal (celler/mm3) fra baseline 
Mean increase from baseline in CD4+ T-cell count (cells/mm3)
Nevirapin, 200 mg to gange dagligt 
Nevirapine, 200 mg BID
Risiko for nedsat plasmakoncentration og klinisk effekt af lopinavir og ritonavir (se pkt. 
Herbal preparations containing St John's wort (Hypericum perforatum) due to the risk of decreased plasma concentrations and reduced clinical effects of lopinavir and ritonavir (see section 4.5).
Hver ml indeholder: 80 mg lopinavir og 20 mg ritonavir . 
Each ml contains: lopinavir 80 mg and ritonavir 20 mg.
På grund af lopinavir/ritonavirs CYP3A-hæmning, forventes koncentrationen af alfuzosin at stige. 
Due to CYP3A inhibition by lopinavir/ritonavir, concentrations of alfuzosin are expected to increase.
Derved øges risikoen for alvorlige arytmier forårsaget af dette lægemiddel (se pkt. 
Thereby, increasing the risk of serious arrhythmias from this agent (see section 4.5).
På grund af lopinavir/ritonavirs CYP3A-hæmning forventes koncentrationen af lomitapid at stige. 
Due to CYP3A inhibition by lopinavir/ritonavir, concentrations of lomitapide are expected to increase.
Forhøjede plasmakoncentrationer af lurasidon som kan forøge risikoen for alvorlige og/eller livstruende reaktioner (se pkt. 
Increased plasma concentrations of lurasidone which may increase the potential for serious and/or lifethreatening reactions (see section 4.5).
Serumkoncentrationen kan øges på grund af lopinavir/ritonavirs hæmning af CYP3A og P-gp. 
Serum concentrations may be increased due to CYP3A and P-gp inhibition by lopinavir/ritonavir.
HMG-CoA-reduktasehæmmere 
Lipid-modifying agents HMG Co-A Reductase Inhibitors
+ 4% (95% CI: -1, 9) (n=19) *Andel af forsøgspersoner som havde hiv-1 < 400 kopier/ml og fortsatte på studie-behandling 
*Proportion of subjects who had HIV-1 < 400 copies/ml and had remained on study treatment
Fluticasonpropionat, 50 µg intranasalt 4 gange dagligt: Plasmakoncentrationer ↑ Kortisolniveauer ↓ 86% 
Fluticasone propionate, 50 µg intranasal 4 times daily:
Forhøjede plasmakoncentrationer af vardenafil (se pkt. 
Increased plasma concentrations of vardenafil (see sections 4.4 and 4.5)
Øget koncentration forventes på grund af lopinavir/ritonavirs hæmning af CYP3A. 
Concentrations are expected to increase due to CYP3A inhibition by lopinavir/ritonavir.
Lopinavir-ritonavir-niveauerne kan stige ved stop af behandling med perikon. 
Lopinavir and ritonavir levels may increase on stopping St John's wort.
På grund af lopinavir/ritonavirs CYP3A-hæmning af pimozid forventes koncentrationen at stige. 
Due to CYP3A inhibition by lopinavir/ritonavir, concentrations of pimozide are expected to increase.
På grund af lopinavir/ritonavirs hæmning af CYP3A4. 
Due to CYP3A4 inhibition by lopinavir/ritonavir.
• Hvis ”ml" markering på kraven er mindre end den ordinerede dosis, træk mere opløsning op, 
• If the ‘ml' mark on the collar is less than the prescribed dose, draw up more solution to the prescribed dose.
− 120 ml (2 flasker x 60 ml) med 2 x 2 ml sprøjter med 0,1 ml inddeling til voluminer op til 2 ml. 
Two pack sizes are available for Kaletra oral solution: - 120 ml (2 bottles x 60 ml) with 2 x 2 ml syringes with 0.1 ml graduations
Glecaprevir/pibrentasvir Serumkoncentrationen kan øges på grund af lopinavir/ritonavirs hæmning af P-glycoprotein, 
Glecaprevir/pibrentasvir Serum concentrations may be increased due to P-glycoprotein, BCRP and OATP1B inhibition by lopinavir/ritonavir.
På grund af lopinavir/ritonavirs hæmning af CYP3A forventes koncentrationen af quetiapin at stige. 
Due to CYP3A inhibition by lopinavir/ritonavir, concentrations of quetiapine are expected to increase.
Forhøjede plasmakoncentrationer af ranolazin, som kan forøge risikoen for alvorlige og/eller livstruende reaktioner (se pkt. 
Increased plasma concentrations of ranolazine which may increase the potential for serious and/or lifethreatening reactions (see section 4.5).
• betændelse i galdegangen; 
• inflammation of the pancreas;
Brug af dosering en gang dagligt bør forbeholdes de voksne patienter, som kun har meget få proteasehæmmer(PI)-associerede mutationer ( f.eks. færre end 3 PI-mutationer i tråd med resultaterne fra et klinisk studie, se pkt. 
The use of a once-daily dosing should be limited to those adult patients having only very few protease inhibitor (PI) associated mutations (i.e. less than 3 PI mutations in line with clinical trial results, see section 5.1 for the full description of the population) and should take into account the risk of a lesser sustainability of the virologic suppression (see section 5.1) and higher risk of diarrhoea (see section 4.8) compared to the recommended standard twice-daily dosing.
Sekalealkaloider 
Ergot alkaloids
På grund af lopinavir/ritonavirs hæmning af CYP3A. 
Due to CYP3A inhibition by lopinavir/ritonavir.
Koncentrationerne kan øges på grund af lopinavir/ritonavirs hæmning af CYP3A. 
Concentrations may be increased due to CYP3A inhibition by lopinavir/ritonavir.
• forstoppelse; 
• constipation;
Alvorlig nedsat leverfunktion. 
Severe hepatic insufficiency.
Administration af Kaletra i kombination med efavirenz eller nevirapin til patienter under 6 måneder anbefales ikke. 
BSA (m2) = √ (Height (cm) X Weight (kg) / 3600) It is recommended that Kaletra not be administered in combination with efavirenz or nevirapine in patients less than 6 months of age.
(Lopinavir/ritonavir 400/100 mg 2 gange dagligt) 
(Lopinavir/ritonavir 400/100 mg BID)
Til børn som vejer mindre end 40 kg eller med en legemsoverflade (BSA) på mellem 0,5 og 1,4 m2 , og som er i stand til at synke tabletter, se produktresuméet for Kaletra 100 mg/25 mg tabletter. 
The adult dose of Kaletra tablets (400/100 mg twice daily) may be used in children 40 kg or greater or with a Body Surface Area (BSA)* greater than 1.4 m2. For children weighing less than 40 kg or with a BSA between 0.5 and 1.4 m2 and able to swallow tablets, please refer to the Kaletra 100 mg/25 mg tablets Summary of Product Characteristics.
Opioider 
Opioids
Pakningsstørrelser og yderligere oplysninger Kaletra indeholder: 
Other side effects that have been reported with Kaletra:
Påbegyndt behandling med perikon bør stoppes, og hvis det er mulig bør de virale-niveauer kontrolleres. 
If a patient is already taking St John's wort, stop St John's wort and if possible check viral levels.
4.3) idet alfuzosin-relateret toksicitet, inklusive hypotension, kan være forøget. 
Concomitant administration of Kaletra and alfuzosin is contraindicated (see section 4.3) as alfuzosin-related toxicity, including hypotension, may be increased.
Præventionsmidler 
Contraceptives
Lovastatin, simvastatin: Markant forøgede plasmakoncentrationer på grund af lopinavir/ritonavirs hæmning af CYP3A. 
Markedly increased plasma concentrations due to CYP3A inhibition by lopinavir/ritonavir.
AUC: ↑ 153% Cmax: ↑ 55% 
AUC: ↑ 153%
Samtidig administration af riociguat og Kaletra anbefales ikke (se pkt. 
The co-administration of riociguat with Kaletra is not recommended (see section 4.4 and refer to riociguat SmPC).
Serumkoncentrationen kan øges på grund af lopinavir/ritonavirs hæmning af CYP3A 
Serum concentrations may be increased due to CYP3A inhibition by lopinavir/ritonavir.
Samtidig administration af øgede fosamprenavir-doser (1400 mg to gange dagligt med Kaletra (533/133 mg to gange dagligt) til proteasehæmmer-erfarne patienter resulterede i en højere forekomst af gastrointestinale bivirkninger og stigninger i triglycerider med kombinationsregimet uden stigning i den virologiske effekt ved sammenligning med standarddoser af fosamprenavir/ritonavir. 
protease inhibitor-experienced patients resulted in a higher incidence of gastrointestinal adverse events and elevations in triglycerides with the combination regimen without increases in virological efficacy, when compared with standard doses of fosamprenavir/ritonavir.
Samtidig administration af vorapaxar og Kaletra anbefales ikke (se pkt. 
The co-administration of vorapaxar with Kaletra is not recommended (see section 4.4 and refer to the vorapaxar SmPC).
Midler mod urinsyregigt 
Renal and urinary disorders